Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Choreo LLC

Choreo LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,744 shares of the medical research company’s stock after acquiring an additional 1,947 shares during the quarter. Choreo LLC’s holdings in Thermo Fisher Scientific were worth $7,139,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Tectonic Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 2.8% in the 4th quarter. Tectonic Advisors LLC now owns 3,224 shares of the medical research company’s stock valued at $1,678,000 after acquiring an additional 89 shares during the last quarter. Nvwm LLC increased its stake in Thermo Fisher Scientific by 0.7% during the fourth quarter. Nvwm LLC now owns 3,101 shares of the medical research company’s stock valued at $1,613,000 after purchasing an additional 22 shares during the last quarter. Confluence Wealth Services Inc. lifted its position in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Confluence Wealth Services Inc. now owns 2,636 shares of the medical research company’s stock worth $1,515,000 after buying an additional 23 shares during the last quarter. Lion Street Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 32.9% in the 4th quarter. Lion Street Advisors LLC now owns 497 shares of the medical research company’s stock valued at $259,000 after buying an additional 123 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Thermo Fisher Scientific by 18.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 56,387 shares of the medical research company’s stock worth $28,502,000 after acquiring an additional 8,722 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $581.72 on Thursday. The company’s 50-day moving average price is $544.31 and its two-hundred day moving average price is $571.88. The stock has a market cap of $222.51 billion, a PE ratio of 35.19, a price-to-earnings-growth ratio of 4.06 and a beta of 0.77. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock buyback plan on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms have recently commented on TMO. Barclays lowered their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird dropped their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Scotiabank boosted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday. Wells Fargo & Company lifted their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $658.00.

Insider Transactions at Thermo Fisher Scientific

In other news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 9,000 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the transaction, the chief executive officer now directly owns 14,608 shares in the company, valued at $8,076,178.88. The trade was a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,125 shares of company stock valued at $16,207,439 over the last three months. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.